Chimeric antigen receptor–modified T-cell (CAR-T) and bispecific T-cell engagers (BiTEs) are both novel anticancer immunotherapies that redirect T-cell specificity against a tumor-specific antigen. As more of these costly therapies are approved, many for overlapping indications and cancer stages, determining their value and selecting the right treatment for the right patient has become increasingly complex.
CAR-T therapies require the extraction of T cells from the patient;